Case Report – Glioblastoma Long-Term Survival with DCA Therapy

• 52 year old male diagnosed with a left parietal glioblastoma multiforme in 2013
• treated with tumour debulking surgery and standard course of low dose chemo combined with radiation
• low blood cell counts due to chemo, dose reduction required
• monthly temozolomide chemo x 1 year (dose reduced) combined with DCA prescribed by Dr. Khan
• prognosis for survival with maximal standard therapy (surgery + chemo + radiation) was 12 – 18 months
• monitored by MRI and Maintrac CTC counts
• CTC increased in 2014, decided to start SEF chemo, completed 28 cycles over 1.5 years, reduction of CTC count
• continued DCA after SEF chemo, minimal side effects
• small therapy adjustments based on CTC and MRI results (boswellia, CoQ10, oleanolic acid, hormone replacement, heavy metal detox)
• patient remains alive and well 9 years after diagnosis, no regrowth

This is an educational case report of a patient treated at Medicor. Every case is unique, not all patients achieve cancer reduction or remission with therapy. Case reports are not meant to imply a guarantee of specific results, but to illustrate what is possible with our cancer therapy protocols.